



Family/Last name

Date of birth

Given name(s)

Patient identifiers

Date of request

Accession/Laboratory number

Elements in **black text** are CORE. Elements in **grey text** are NON-CORE.

indicates multi-select values indicates single select values

SCOPE OF THIS DATASET

Protocol followed

- Children's Oncology Group (COG)
 International Society of Paediatric Oncology (SIOP)
 Not known

PREVIOUS THERAPY

- Information not provided
 No previous chemotherapy administered
 Previous chemotherapy administered

Clinical information guiding previous therapy, *specify if available*

OPERATIVE PROCEDURE

- Not specified
 Enucleation
 Partial nephrectomy
 Total or radical nephrectomy
 Other, *specify*

PREOPERATIVE RUPTURE OR INTRAOPERATIVE SPILLAGE

- Not identified
 Identified
 Cannot be determined, *specify*

ACCOMPANYING/ATTACHED STRUCTURES

(select all that apply)

- Not submitted
 Adrenal gland
 Other, *specify*

SPECIMEN LATERALITY

- Not specified/Not applicable
 Left
 Right
 Other (e.g., horseshoe kidney, single kidney), *specify*

SPECIMEN WEIGHT

g

- Cannot be assessed

TUMOUR FOCALITY

- Cannot be determined
 Unifocal
 Multifocal

Specify number of tumours

TUMOUR DIMENSIONS^a

Nodule 1

Greatest dimension mm

Additional dimensions mm x mm

Nodule 2

Greatest dimension mm

Additional dimensions mm x mm

- Cannot be assessed, *specify*

^a Specify for each nodule, or for the two nodules that determine the stage and/or histologic classification.

BLOCK IDENTIFICATION KEY 

(List overleaf or separately with an indication of the nature and origin of all tissue blocks)

RENAL SINUS INVOLVEMENT (select all that apply) 

- Cannot be determined
- Not identified
- Renal sinus vessel involvement by viable tumour with negative margin^b
- Invasion of the wall of the ureter or collecting system outside of the kidney by viable tumour (but completely resected with negative margin)^b
- More than minimal renal sinus soft tissue invasion present (but completely resected with negative margin)^b
- Minimal renal sinus soft tissue invasion by viable tumour present (<5 mm in greatest dimension and >5 mm from a margin)^c

^b Criteria for local stage II by both COG and SIOP.

^c Allowed within local stage I by COG, considered stage II by SIOP.

RENAL CAPSULE PENETRATION 

- Cannot be assessed
- No viable tumour outside the renal capsule
- Viable tumour outside the renal capsule (including adrenal gland) that **is not** surrounded by a fibrous pseudocapsule, with negative margins^d
- Viable tumour outside the renal capsule or within the adrenal gland that **is** surrounded by a fibrous pseudocapsule, with negative margins^e

^d Supports local stage II by SIOP and COG.

^e Supports local stage II for COG; allowed within local stage I for SIOP.

PRIMARY TUMOUR EXCISED IN ONE PIECE 

- Cannot be assessed
- Tumour excised in one piece
- Tumour excised in more than one piece^f

^f Applicable only for COG staging, for which excision in more than one piece supports local stage III.

NEPHROGENIC RESTS^g 

- Cannot be assessed
- Not identified
- Present (select all that apply)
 - Intralobar
 - Single
 - Multiple
 - Perilobar
 - Single
 - Multiple
 - Diffuse, hyperplastic
 - Unclassified

^g Nephrogenic rests are not included in staging criteria.

HISTOLOGICAL TUMOUR TYPE 

(Value list based on the World Health Organization Classification of Paediatric Tumours (2023))

- Wilms tumour (nephroblastoma)
 - Favourable histology
 - Focal anaplasia
 - Diffuse anaplasia
- Nephrogenic rest only (without Wilms tumour)
 - Intralobar
 - Perilobar
- Mesoblastic nephroma
 - Cellular
 - Classic
 - Mixed
- Paediatric cystic nephroma
- Cystic partly differentiated nephroblastoma
- Metanephric stromal tumour
- Metanephric adenoma
- Metanephric adenofibroma
- Ossifying renal tumour of infancy
- Clear cell sarcoma of the kidney
- Rhabdoid tumour of the kidney
- Anaplastic sarcoma of the kidney (DICER-1 associated)
- Other, *specify*

--	--

POST-THERAPY HISTOLOGICAL CLASSIFICATION OF WILMS TUMOUR 

- Not applicable^h

Low risk tumours

- Completely necrotic (100% necrosis although residual tubules from nephrogenic rests may be present)

Intermediate risk tumours

- Favourable histology, epithelial type ($\leq 66\%$ necrosis; $>66\%$ of viable component epithelial and $<10\%$ blastema)
- Favourable histology stromal type ($\leq 66\%$ necrosis; $>66\%$ of viable component stromal and $<10\%$ blastema)
- Favourable histology mixed type ($\leq 66\%$ necrosis with viable component containing at least two components, none of which comprise more than two thirds of the viable tumour, or tumours that are 10-66% blastema)
- Favourable histology, regressive type (66-99% necrosis)
- Focal anaplasia (except blastema type)ⁱ

High risk tumours

- Blastema type ($\leq 66\%$ necrosis with $>66\%$ viable blastema component)
- Diffuse anaplasiaⁱ

^h Not post-therapy or not Wilms tumour.

ⁱ Focal and diffuse anaplasia are included in the post-therapy risk stratification by SIOP, but are treated by separate clinical protocols by COG.

MARGIN STATUS 

- Cannot be assessed
- Not involved

Distance of viable tumour from closest margin mm

Specify closest margin(s), if possible

Involved by viable tumour^j (select all that apply)

- Renal vein margin
- Ureteral margin
- Inked soft tissue or parenchymal margin
- Other, *specify*

Involved by non-viable tumour (select all that apply)

- Renal vein margin^j
- Ureteral margin^j
- Inked soft tissue or parenchymal margin^k
- Other, *specify*

Presence of viable or non-viable tumour in peritoneal or abdominal or pelvic nodules or implants^j

^j Supports local stage III by both COG and SIOP.

^k Supports local stage III by COG, but not by SIOP.

LYMPH NODE STATUS 

- Cannot be assessed
- No nodes submitted or found

Number of lymph nodes examined

- Not involved
- Involved (viable or non-viable tumour)^j

Number of involved lymph nodes

Number cannot be determined

Location of involved lymph nodes (select all that apply)

- Regional
- Non-regional (outside the abdomino-pelvic region)

COEXISTENT PATHOLOGY 

- None identified
- Present, *specify*

ANCILLARY STUDIES 

- Not performed
- Performed (select all that apply)

Immunohistochemistry, *specify test(s) and result(s)*

Molecular genetic testing, *specify test(s) and result(s)*

Other, *record test(s), methodology and results*

Representative blocks for ancillary studies, *specify those blocks best representing tumour and/or normal tissue for further study*

HISTOLOGICALLY CONFIRMED DISTANT METASTASIS 

- Not applicable
- Not identified
- Present, *specify site(s)*

PATHOLOGICAL STAGING 

Pathologic staging system used

- Children's Oncology Group (COG)
- International Society of Paediatric Oncology (SIOP)

Local stage (based on the data elements for each stage)

- Local stage I All staging elements are consistent with local stage I, and none indicate local stages II or III
- Local stage II Presence of any staging element supporting local stage II and no parameters for local stage III
- Local stage III Presence of any staging element for local stage III
- Local stage not determined